TSE:PMN ProMIS Neurosciences (PMN) Stock Forecast, Price & News C$6.80 +0.19 (+2.87%) (As of 06/7/2023 ET) Add Compare Share Share Today's RangeC$6.80▼C$6.8050-Day RangeC$6.35▼C$11.0052-Week RangeC$5.60▼C$12.22Volume2,599 shsAverage Volume1,951 shsMarket CapitalizationC$58.34 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsInsider TradesHeadlinesSocial MediaProfileChartCompetitorsEarningsInsider TradesHeadlinesSocial Media About ProMIS Neurosciences (TSE:PMN) StockProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Read More Receive PMN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProMIS Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address PMN Stock News HeadlinesMay 31, 2023 | americanbankingnews.comProMIS Neurosciences (TSE:PMN) Trading Up 0.7%May 16, 2023 | finanznachrichten.deProMIS Neurosciences Inc.: ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent HighlightsJune 8, 2023 | Edge On The Street (Ad)New "Mined in America" Lithium Opportunities?The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.May 8, 2023 | finance.yahoo.comProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s DiseaseApril 27, 2023 | theglobeandmail.comClosing Bell: Promis Neurosciences Inc up on Wednesday (PMN)April 19, 2023 | theglobeandmail.comClosing Bell: Promis Neurosciences Inc down on Wednesday (PMN)April 10, 2023 | proactiveinvestors.comProMIS Neurosciences submits IND application for Alzheimer's treatmentApril 10, 2023 | finance.yahoo.comProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310June 8, 2023 | Edge On The Street (Ad)New "Mined in America" Lithium Opportunities?The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.March 29, 2023 | finance.yahoo.comLead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023March 13, 2023 | finance.yahoo.comProMIS Neurosciences to Present New Preclinical Data for PMN310 at AD/PD 2023March 13, 2023 | finance.yahoo.comProMIS Neurosciences Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2023 Annual MeetingJanuary 22, 2023 | reuters.comPMN.TO - | Stock Price & Latest News | ReutersOctober 26, 2022 | seekingalpha.comPMN:CA ProMIS Neurosciences, Inc.October 17, 2022 | finance.yahoo.comProMIS Neurosciences, Inc. (PMN)August 15, 2022 | finance.yahoo.comCan ProMIS Neurosciences (TSE:PMN) Afford To Invest In Growth?August 4, 2022 | financialpost.comProMIS Neurosciences Presents at 2022 Alzheimer's Association International ConferenceAugust 2, 2022 | finance.yahoo.comProMIS Neurosciences Presents at 2022 Alzheimer’s Association International ConferenceJuly 27, 2022 | finance.yahoo.comProMIS Neurosciences to Present at 2022 Alzheimer’s Association International ConferenceJuly 15, 2022 | nasdaq.comProMIS Neurosciences Rings the Closing BellJuly 1, 2022 | ca.finance.yahoo.comProMIS at 52-Week HighJune 27, 2022 | finanznachrichten.deProMIS Neurosciences Inc.: ProMIS Neurosciences announces reverse share split to meet NASDAQ listing criteriaJune 27, 2022 | finance.yahoo.comPROMIS ANNOUNCES REVERSE SHARE SPLIT TO MEET NASDAQ LISTING CRITERIAJune 22, 2022 | ca.finance.yahoo.comStocks in play: ProMIS Neurosciences Inc.May 13, 2022 | ca.finance.yahoo.comStocks in play: ProMIS Neurosciences IncMay 13, 2022 | finance.yahoo.comProMIS Neurosciences Announces First Quarter 2022 ResultsMay 13, 2022 | finance.yahoo.comProMIS Holds Annual and Special Meeting of Shareholders All Resolutions ApprovedSee More Headlines PMN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PMN Company Calendar Last Earnings5/15/2023Today6/08/2023Next Earnings (Estimated)8/11/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolTSE:PMN Previous SymbolTSE:AMF CUSIPN/A CIKN/A Webwww.promisneurosciences.com Phone+1-416-8476898FaxN/AEmployees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($3.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-20,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-837.71% Return on Assets-168.33% Debt Debt-to-Equity Ratio108.33 Current Ratio0.51 Quick Ratio1.30 Sales & Book Value Annual SalesC$7,558.00 Price / Sales7,719.50 Cash FlowC$0.48 per share Price / Cash Flow14.07 Book ValueC($0.72) per share Price / Book-9.44Miscellaneous Outstanding Shares8,580,000Free FloatN/AMarket CapC$58.34 million OptionableNot Optionable Beta1.15 Key ExecutivesDr. Neil R. Cashman M.D. (Age 70)Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director Comp: $99kMr. Daniel E. Geffken M.B.A. (Age 65)MBA, Chief Financial Officer Comp: $122.28kMr. Gavin T. Malenfant (Age 60)Chief Operating Officer Comp: $53.32kDr. Johanne Kaplan Ph.D.Chief Devel. OfficerDr. Gail M. Farfel Ph.D. (Age 58)Chief Exec. Officer Dr. Ernest D. Bush Ph.D.Head of Pharmacology/Toxicology & Sr. ConsultantDr. David Wishart Ph.D.Chief Physics OfficerMr. Dennis Chen Ph.D.Head of Manufacturing & Sr. ConsultantDr. Larry Douglas Altstiel M.D. (Age 72)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsMicrobix BiosystemsTSE:MBXEmerald Health TherapeuticsCVE:EMHMedicenna TherapeuticsTSE:MDNACovalon TechnologiesCVE:COVPediapharmCVE:PDPView All CompetitorsInsidersEugene Warren WilliamsBought 1,000 shares on 12/16/2022Total: C$6,324.00 ($6.32/share)Eugene Warren WilliamsBought 1,000 shares on 12/12/2022Total: C$6,902.00 ($6.90/share)Eugene Warren WilliamsBought 1,000 shares on 12/7/2022Total: C$7,466.40 ($7.47/share)Eugene Warren WilliamsBought 1,000 shares on 12/2/2022Total: C$8,132.80 ($8.13/share)Patrick D. KirwinBought 4,000 shares on 8/16/2022Total: C$30,600.00 ($7.65/share)View All Insider Transactions PMN Stock - Frequently Asked Questions How have PMN shares performed in 2023? ProMIS Neurosciences' stock was trading at C$6.10 at the beginning of 2023. Since then, PMN shares have increased by 11.5% and is now trading at C$6.80. View the best growth stocks for 2023 here. When is ProMIS Neurosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023. View our PMN earnings forecast. How were ProMIS Neurosciences' earnings last quarter? ProMIS Neurosciences, Inc. (TSE:PMN) posted its quarterly earnings data on Monday, May, 15th. The company reported ($0.78) earnings per share for the quarter. What other stocks do shareholders of ProMIS Neurosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other ProMIS Neurosciences investors own include CRISPR Therapeutics (CRSP), Aurora Cannabis (ACB), Biocept (BIOC), Spectra7 Microsystems (SEV), Flexion Therapeutics (FLXN), Onconova Therapeutics (ONTX), TherapeuticsMD (TXMD), Bonavista Energy Co. (BNP.TO) (BNP) and QEP Resources (QEP). What is ProMIS Neurosciences' stock symbol? ProMIS Neurosciences trades on the Toronto Stock Exchange (TSX) under the ticker symbol "PMN." How do I buy shares of ProMIS Neurosciences? Shares of PMN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What is ProMIS Neurosciences' stock price today? One share of PMN stock can currently be purchased for approximately C$6.80. How much money does ProMIS Neurosciences make? ProMIS Neurosciences (TSE:PMN) has a market capitalization of C$58.34 million and generates C$7,558.00 in revenue each year. The company earns C$-20,930,000.00 in net income (profit) each year or C($3.70) on an earnings per share basis. How can I contact ProMIS Neurosciences? ProMIS Neurosciences' mailing address is 1920 Yonge St Suite 200, TORONTO, ON M4S 3E2, Canada. The official website for the company is www.promisneurosciences.com. The company can be reached via phone at +1-416-8476898. This page (TSE:PMN) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProMIS Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.